Skip to main content

Table 3 Associates with bone loss in 92 rheumatoid arthritis patients followed for 10 years

From: Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era

  Change in bone mineral density
  Femoral neck Total hip Spine L1-4
  0-2 yrs 2-10 yrs 0-2 yrs 2-10 yrs 0-2 yrs 2-10 yrs
  Beta Beta Beta Beta Beta Beta
  p value p value p value p value p value p value
Age (yrs) - - - - - B 0.244 P = 0.048
Women (N/Y) - B-0.029 P = 0.027 - B-0.039 P = 0.004 - B-0.104 P = 0.000
Menopause (N/Y) - B-0.033 P = 0.049 B 0.016 P = 0.076 B-0.053 P = 0.003 - B-0.051 P = 0.063
Smoking (N/Y) - B-0.028 p = 0.036 - B-0.024 P = 0.080 - -
RF (N/Y) - B-0.030 P = 0.030 - B-0.029 P = 0.047 - B-0.053 P = 0.044
MHAQ (0–3) B −0.027 p = 0.034 - - - - -
ESR (mm/hr) - - - - B-0.189 P = 0.092  
DAS28ESR3 B −0.010 P = 0.030 B-0.015 P = 0.057 - B-0.016 P = 0.055 B-0.013 P = 0.037 -
Ever use of biologic DMARDs (N/Y) B-0.023 P = 0.024 - B-0.019 P = 0.058 - B-0.023 P = 0.091 B-0.052 P = 0.039
Cumulative equivalent prednisolon (gram) B-0.002 P = 0.024 - B-0.003 P = 0.003 - - -
  1. Variables are tested for their association with change in hip and spine bone density for the follow up periods 0–2 years and 2–10 years in early rheumatoid arthritis patients using univariate linear regression analysis. Unstandardized Beta values are only shown for variables with a p value ≤ 0.1.
  2. Yrs: Years; N/Y: No/yes; RF: Rheumatoid factor; MHAQ: Modified health assessment questionnaire; ESR: Erythrocyte sedimentation rate; DAS28ESR3: Disease activity score based on 28 joint count (swollen and tender joints) and ESR; DMARDs: Disease modifying anti-rheumatic drugs.